CLINICAL TRIALS PROFILE FOR VINORELBINE TARTRATE

All Clinical Trials for VINORELBINE TARTRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002813 ↗	Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with cisplatin and vinorelbine in treating patients with refractory or recurrent squamous cell cervical cancer that has not responded to local therapy.
NCT00002813 ↗	Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer	Completed	Gynecologic Oncology Group	Phase 2	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with cisplatin and vinorelbine in treating patients with refractory or recurrent squamous cell cervical cancer that has not responded to local therapy.
NCT00002823 ↗	Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer	Completed	Gustave Roussy, Cancer Campus, Grand Paris	Phase 3	1995-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy given after surgery is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy following surgery with that of surgery alone in treating patients who have stage I, stage II, or stage IIIA non-small cell lung cancer.
NCT00002887 ↗	Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer	Unknown status	Ottawa Regional Cancer Centre	Phase 1	1995-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug is a way to kill more tumor cells. PURPOSE: Phase I trial to study the effects of hydroxyurea plus combination chemotherapy in patients with non-small cell lung cancer.
NCT00002949 ↗	Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis	Completed	National Cancer Institute (NCI)	Phase 1	1996-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy with may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy with vinorelbine and paclitaxel plus radiation therapy in treating patients with advanced cancer arising in the pelvis.
NCT00002949 ↗	Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis	Completed	University of Chicago	Phase 1	1996-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy with may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy with vinorelbine and paclitaxel plus radiation therapy in treating patients with advanced cancer arising in the pelvis.
NCT00003159 ↗	Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1997-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if surgery is more effective with or without preoperative chemotherapy in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying surgery and preoperative chemotherapy to see how well they work compared to surgery alone in treating patients with resectable non-small cell lung cancer.

Clinical Trial Conditions for VINORELBINE TARTRATE

Condition Name

Condition Name for VINORELBINE TARTRATE
Intervention	Trials
Lung Cancer	22
Breast Cancer	11
Prostate Cancer	5
Lymphoma	5

Condition MeSH

Condition MeSH for VINORELBINE TARTRATE
Intervention	Trials
Lung Neoplasms	28
Carcinoma, Non-Small-Cell Lung	27
Breast Neoplasms	21
Hodgkin Disease	10

Clinical Trial Locations for VINORELBINE TARTRATE

Trials by Country

Trials by Country for VINORELBINE TARTRATE
Location	Trials
United States	570
Canada	51
Australia	18
United Kingdom	18
Italy	11

Trials by US State

Trials by US State for VINORELBINE TARTRATE
Location	Trials
California	24
Illinois	22
New York	22
Florida	18
Texas	18

Clinical Trial Progress for VINORELBINE TARTRATE

Clinical Trial Phase

Clinical Trial Phase for VINORELBINE TARTRATE
Clinical Trial Phase	Trials
PHASE2	1
Phase 3	22
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for VINORELBINE TARTRATE
Clinical Trial Phase	Trials
Completed	47
Unknown status	15
Terminated	11

Clinical Trial Sponsors for VINORELBINE TARTRATE

Sponsor Name

Sponsor Name for VINORELBINE TARTRATE
Sponsor	Trials
National Cancer Institute (NCI)	34
Children's Oncology Group	6
Alliance for Clinical Trials in Oncology	5

Sponsor Type

Sponsor Type for VINORELBINE TARTRATE
Sponsor	Trials
Other	91
NIH	35
Industry	23

VINORELBINE TARTRATE Market Analysis and Financial Projection

Last updated: April 23, 2026

Vinorelbine Tartrate: Clinical Trials Update, Market Analysis, and Projection

What is vinorelbine tartrate and how is it positioned commercially?

Vinorelbine tartrate is the salt form of vinorelbine, an anticancer vinca alkaloid used primarily in oncology for systemic therapy. Commercially, vinorelbine is established in multiple geographies as a legacy chemotherapy agent, with product availability shaped by patent/market-exclusivity status, generic competition, and ongoing label expansion in specific indications.

Commercial reality (current period):

• Vinorelbine is a mature oncology drug.
• Pricing and unit economics typically compress post-generic entry and under health-system formularies.
• Uptake depends less on first-time innovation and more on indication-specific guideline positioning, formulation supply, and on-formulary access.

What does the current clinical trials landscape look like?

No complete, reliable trials dataset can be produced from the information available in this chat. Generating a “clinical trials update” requires a contemporaneous registry pull (ClinicalTrials.gov/ICTRP/EU CT database), including trial phase, recruiting status, start/completion dates, endpoints, and sponsor/manufacturer for vinorelbine tartrate specifically (not vinorelbine base or mixed-salt forms). Without that data, any claimed update would be non-actionable and could misstate the pipeline.

What is the vinorelbine tartrate market today?

A complete market analysis requires consistent baselines (global and major markets), including:

• Prescription volume by indication
• Pricing net of rebates (or transparent proxies)
• Access constraints and tender dynamics
• Brand vs generic mix
• Line-of-therapy distribution

This chat does not provide those market inputs. Producing numbers without a traceable dataset would create an analytical gap that cannot be corrected within the constraints.

What market projection can be supported for vinorelbine tartrate?

Projections require at least one of:

• Forecast model inputs (incidence/treated population, share assumptions, penetration curves, dosing patterns)
• Historical sales/volume trends and segmentation by region and indication
• Scenario ranges tied to formulary/access and competitive entry timing

No such dataset is present here. A projection would therefore be structurally unsupported.

---

Key Takeaways

• Vinorelbine tartrate is a mature chemotherapy where market outcomes are driven by formularies, generic penetration, and indication-specific uptake, not new molecular differentiation.
• A clinical trials update and quantified market forecast cannot be produced from the information available in this chat without a validated contemporaneous trials and commercial dataset.
• Any investment or R&D decisioning using quantified pipeline and forecast metrics requires a registry pull and sales/volume dataset tied to vinorelbine tartrate specifically.

---

FAQs

1) Is vinorelbine tartrate a new drug class?

No. It is a legacy cytotoxic vinca alkaloid used in oncology.

2) What drives utilization for vinorelbine in practice?

Access through oncology guidelines and formularies, along with dosing schedules and practical chemotherapy regimen inclusion.

3) Why does generic competition matter for vinorelbine tartrate?

Pricing compression and tender-based selection can reduce brand share and lower revenue even when treated volume remains stable.

4) What trial types typically involve vinorelbine?

Commonly used in combination chemotherapy studies and in regimen optimization within specific cancer types or lines of therapy.

5) What is the minimum data needed for a credible forecast?

A validated trials registry extract plus historical sales/volume by region and indication with generic mix and access constraints.

---

References

No cited sources are included because this response does not present registry-derived trial facts or market numbers.